ausblenden:
Schlagwörter:
OLAPARIB MAINTENANCE THERAPY; POLY(ADP-RIBOSE) POLYMERASE-1;
LIPID-METABOLISM; MECHANISMS; RESISTANCE; COMBINATION; CARCINOMA;
RUCAPARIB; LYMPHOMA; REVEALSReproductive Biology; PARP inhibitors; High-grade serous ovarian cancer; Mass spectrometry
based proteomics; Molecular response profiling; Pathway analysis;
Data-driven protein module discovery; Molecular signaling pathways; PARP
inhibitor resistance; Combination therapy;
Zusammenfassung:
Background Poly (ADP)-ribose polymerase (PARP) inhibitors have entered routine clinical practice for the treatment of high-grade serous ovarian cancer (HGSOC), yet the molecular mechanisms underlying treatment response to PARP1 inhibition (PARP1i) are not fully understood. Methods Here, we used unbiased mass spectrometry based proteomics with data-driven protein network analysis to systematically characterize how HGSOC cells respond to PARP1i treatment. Results We found that PARP1i leads to pronounced proteomic changes in a diverse set of cellular processes in HGSOC cancer cells, consistent with transcript changes in an independent perturbation dataset. We interpret decreases in the levels of the pro-proliferative transcription factors SP1 and beta-catenin and in growth factor signaling as reflecting the anti-proliferative effect of PARP1i; and the strong activation of pro-survival processes NF-kappa B signaling and lipid metabolism as PARPi-induced adaptive resistance mechanisms. Based on these observations, we nominate several protein targets for therapeutic inhibition in combination with PARP1i. When tested experimentally, the combination of PARPi with an inhibitor of fatty acid synthase (TVB-2640) has a 3-fold synergistic effect and is therefore of particular pre-clinical interest. Conclusion Our study improves the current understanding of PARP1 function, highlights the potential that the anti-tumor efficacy of PARP1i may not only rely on DNA damage repair mechanisms and informs on the rational design of PARP1i combination therapies in ovarian cancer.
